20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efectividad y seguridad de salbutamol genérico respecto de salbutamol original en inhalador presurizado de dosis medida, en el tratamiento de la obstrucción bronquial aguda del lactante: Estudio doble ciego Translated title: MDI salbutamol in wheezy infants: An eficcacy and safety comparison study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diversas empresas farmacéuticas comercializan actualmente en Chile salbutamol genérico (SG) en inhalador de dosis medida, cuya equivalencia en efectividad y seguridad respecto del salbutamol original (SO) no se ha estudiado en lactantes. En un diseño prospectivo, 115 niños de 1 a 23 meses que presentaban un episodio agudo de obstrucción bronquial moderado o severo (Puntaje de Tal modificado 6-10) fueron distribuidos aleatoriamente para recibir SG (Cipla, India) o SO (GSK, Inglaterra), según Normas del Ministerio de Salud. Al cabo de la primera hora de observación, el tratamiento fue exitoso (puntaje = 5) en 88,1% (52/59) del grupo SG y 87,5% (49/56) del grupo SO, diferencia no significativa. Los grupos también fueron similares en puntaje clínico, frecuencia respiratoria, saturometría, frecuencia cardíaca y reducción de puntaje entre el ingreso y la primera hora. Al término de la segunda hora, hubo 5,1% (3/59) de fracasos en SG y 5,4% (3/56) en SO. Ninguno de los parámetros estudiados tuvo diferencias estadísticas significativas. Se concluye que el SG estudiado es similar al SO en efectividad y seguridad para el tratamiento de episodios agudos de obstrucción bronquial en lactantes

          Translated abstract

          Many pharmaceutical companies comercialize generic salbutamol (GS) in metered-dose inhalers in Chile. However, the equivalence in eficcacy and safety of the GS has not been compared with the original salbutamol (OS) in children less than two years. In a prospective study we studied 115 infants (1-23 months) presenting a moderate or severe acute wheezing episode. They were randomly allocated to receive GS (Cipla, India) or OS (GSK, England) in a protocol of treatment according Chilean National Guidelines. At the end of the first hour of observation, the treatment was successful (score = 5) in 88.1% (52/59) of GS group and 87,5% (49/56) of OS group, non significant difference. Groups were not different in mean clinical score, respiratory frequency, pulse oximetry and cardiac frequency. Mean score fell 2,70 points in GS group and 2,64 points in OS group. At the end of the second hour, treatment was not successful in 5,1% (3/59) in GS group and 5,4% (3/56) in OS group. None of these parameters were statistically different. This study shows that GS and OS are similar in efficacy and safety in the treatment of acute wheezing in infants

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Towards a new classification of ectodermal dysplasias.

          Ectodermal dysplasias (EDs) constitute a large and complex group of diseases characterized by various defects in hair, nails, teeth and sweat glands. Of the 170 EDs described so far, fewer than 30 have been explained at the molecular level with identification of the causative gene. This review proposes a new classification of EDs based on the function of the protein encoded by the mutated gene. The EDs are reviewed in light of the recent molecular and biochemical findings and an attempt is made to classify ED causative genes into four major functional subgroups: cell-cell communication and signalling; adhesion; transcription regulation; and development.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age.

            The aim of this study was to compare the efficacy of salbutamol delivered via a metered-dose inhaler with a spacer and facial mask (MDI-S) vs. a nebulizer (NEB) for the treatment of acute exacerbations of wheezing in children. In a single-blind, prospective, randomized clinical trial, 123 outpatients (1-24 months of age), presenting with "moderate to severe" wheezing, were seen in the emergency department. Children were randomly assigned to one of two salbutamol treatment groups. In the first hour, the MDI-S group received 2 puffs (100 microg/puff) every 10 min for 5 doses, and the NEB group received 0.25 mg/kg every 13 min for 3 doses. If the clinical score was >5 at the end of the first hour, the patients received another hour of the same treatment and also betamethasone (0.5 mg/kg intramuscular). On enrollment and after the first and the second hour of treatment each child had a validated clinical score assigned by a blinded investigator. There were no differences at the time of admission to the emergency department between groups in clinical score or demographic data. Success (clinical score 0.05). We conclude that in this study population, children less than 2 years of age with moderate-severe exacerbations of wheezing responded faster to salbutamol delivered by MDI with a spacer and facial mask than to salbutamol delivered by nebulizer. Copyright 2000 Wiley-Liss, Inc.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Drug delivery to the small airways.

              P Thompson (1998)
                Bookmark

                Author and article information

                Journal
                rcp
                Revista chilena de pediatría
                Rev. chil. pediatr.
                Sociedad Chilena de Pediatría (Santiago, , Chile )
                0370-4106
                October 2004
                : 75
                : suppl 1
                : 32-36
                Affiliations
                [02] orgnameHospital Padre Hurtado orgdiv1Unidad de Emergencia Infantil Chile
                [01] orgnameMinisterio de Salud orgdiv1Programa de Salud Respiratoria Chile
                Article
                S0370-41062004000700006 S0370-4106(04)07500006
                10.4067/S0370-41062004000700006
                e8acae36-13b0-4317-9fdf-acdf755ae3b3

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 16, Pages: 5
                Product

                SciELO Chile

                Categories
                ARTÍCULOS ORIGINALES

                salbutamol,wheezy,tratment,SBO,lactantes,MDI,infants,tratamiento
                salbutamol, wheezy, tratment, SBO, lactantes, MDI, infants, tratamiento

                Comments

                Comment on this article